



DTAus – ASM 2023

The new era in AD therapies

Date: Friday 6 October 2023

Time: 10:00AM-4:45PM

Location: Sydney University NSW

Conference Program

Time	TOPIC
09:15-10:00am	Registration/Welcome Tea & Coffee
10:00 -10:05am	Conference Opening Dr Chrys Pulle
10:05 -10:35am	Australian Safety and Quality Commission on Healthcare and National Clinical Trials Framework Dr Bernadette Aliprandi-Costa
10:35 -11:05am	Generalizability of Trial results and eligibility parameters A/Prof Michael Woodward
11:05 -11:25am	Adnet- recruitment and retention in Alzheimer's clinical trials Prof Chris Rowe
11:35 -11:55am	Trial Co-ordination in Modern Era- The Good, Bad and The Ugly CRC Perspective Roseanne Hogarth and Viral Ghandi
11:55 -12:15pm	How best to use Lecanemab to modify Alzheimer's disease Eisai presentation
12:15 - 1:00pm	LUNCH
1:00 - 1:15pm	Dementia Trials Australia 2023 AGM All
1:15 - 1:45pm	Low Intensity Ultrasound- a novel treatment strategy for Alzheimer's Disease Jürgen Götz
1:45 - 2:15pm	Neuroinflammatory biomarkers in Alzheimer's Disease. C J Barnum
2:15 - 2:45pm	Debate on the Ethics of Placebo Controlled trials Prof Steve Macfarlane and A/Prof Roger Clarnette
2:45 - 3:00pm	Cerecin Presentation Dr Lars Nelleman
3:00 - 3:15pm	AFTERNOON TEA
3:15 - 3:30pm	Teletrials- Is this the way of the future? Kaye Hewson
3:30 - 3:45pm	Targeted modification of brain cortisol – a novel, non-amyloid approach Actinogen- Steven Gourlay
3:45 - 4:15pm	Alzheimer's Dementia Trials Update 2023 and future AD Therapies- Genetic Therapy, Stem Cell Therapy, CAR-T cells etc A/Prof Roger Clarnette
4:15 - 4.30pm	Nutricia Fiona Justice
4.30 – 4.50pm	Panel Discussion - Hot Topics in Dementia trials A/Prof Michael Woodward and Prof Chris Rowe
4:50 - 5:00pm	Closing



DTAus

DTAus Chair

Dr Chrys Pulle

ChrysRanjeev.Pulle@health.qld.gov.au

DTAus Executive

Prof. Chris Rowe

Dr. Karyn Boundy

A/Prof. Michael Woodward

A/Prof. Roger Clarnette

A/Prof. Kathryn Goozee

Ms. Roseanne Hogarth

Dr. Cathy Short

Dr Ishita Batta

Dr Sally Johns



Registration Details

DTAus Annual Scientific Meeting, University of Sydney,

06th October, 2023

Face to Face Registration Fee: \$200

Registration Link: <https://www.trybooking.com/CHSHB>

Dr Chrys Pulle, MB BS FRACP (Chair)

Staff Specialist Geriatrician and Director Internal Medicine Dementia Research Unit at The Prince Charles Hospital, Metro North Hospital and Health Service, QLD Health.

Other appointments:

- Chair of Dementia Trials Australia 2019 – current.
- President of the QLD Div ANZSGM 2017 – current.
- Co chair Australasian Consortium of Centres for Clinical Cognitive Research 2016-2018.
- Senior Lecturer, Northside Clinical School University of QLD
- Chair Network of Fracture Education and Research, The Prince Charles Hospital.



Dr Bernadette Aliprandi-Costa ACSQHC

Manager of the Safety and Quality Improvement Systems team at the Australian Commission on Safety and Quality in Health Care

Bernadette is the Manager of the Safety and Quality Improvement Systems team at the Australian Commission on Safety and Quality in Health Care (the Commission). The Commission is a corporate Commonwealth entity and part of the Health portfolio of the Australian Government. The Commission is an Australian government agency that leads and coordinates national improvements in safety & quality of health care, working in partnership with the Australian Government, state and territory governments, private sector, patients, clinicians, managers and health care organizations.

Bernadette is a clinician who holds a PhD in health outcomes research from the University of Sydney Medical School and has led programs of work over two decades in health service performance measurement and reporting; the development of quality standards and funding models for clinical trial services and the design and implementation of clinical quality registries.



A/Professor Michael Woodward AM MB BS MD FRACP

Head of Aged Care Research and Memory Clinic, Austin Health, Heidelberg, VIC.

Other appointments:

- Associate Professor Michael Woodward is Head of Aged Care Research and the Memory Clinic at Austin Health in Melbourne, Victoria, and an Honorary Medical advisor for Dementia Australia. He is a specialist in geriatric medicine with major interests in the treatment of Alzheimer's disease (AD) and other dementias. He is Principal Investigator for numerous research trials of new therapies for AD and related disorders. He is Past President of the AC4R – the Australasian Consortium of Centres for Clinical Cognitive Research that brings together researchers into therapeutic agents for dementia. He was a member of the Alzheimer's Australia Victoria Board, being appointed their chief medical advisor and chairing their research foundation, which administers over \$2 million of research funding.
- Michael Woodward's publication record includes over 120 original research and review articles. He has been awarded his MD on the overlap between the dementia syndromes. More recent research interests have focused on characterizing the frontal variant of Alzheimer's Disease. He is a Fellow of the Australian Association of Gerontology (AAG), the Australian and New Zealand Society for Geriatric Medicine, the Australian Wound Management Association (AWMA) and the Royal Australasian College of Physicians (RACP) and has long served each of these professional bodies, including becoming President of AWMA and AAG (Vic) and chairing the Committee for Physician Training that oversaw the training of all RACP trainees.



Professor Christopher Rowe BMBS, FRACP, MD, FAANMS

Director of Molecular Imaging Research at Austin Health and the University of Melbourne, VIC.

Other appointments:

- Christopher Rowe is a nuclear medicine physician and neurologist, with over 20 years of experience in dementia research and patient care.
- He is the Principal Investigator and Director of the Australian Dementia Network (ADNeT) established across the nation in late 2018 with funding from the Federal Government through the NHMRC National Institute of Dementia Research and philanthropic donors. His research focus is molecular brain imaging of neurodegenerative diseases, particularly Alzheimer's disease, for better understanding, earlier more accurate detection, and to facilitate development of early therapeutic interventions.
- He is a 2019 Highly Cited Researcher (top 1% world-wide for neuroscience) and has received international awards for his work including the US Society of Nuclear Medicine Kuhl-Lassen Award for Outstanding Contribution to Brain Imaging and the Christopher Clark Award for advancing human amyloid imaging.



Professor Jürgen Götz

Lesleigh Green - Bill and Nancy Green Endowed Chair in Dementia Research and inaugural Director of the Clem Jones Centre for Ageing Dementia Research at the Queensland Brain Institute

Professor Jürgen Götz is the Lesleigh Green - Bill and Nancy Green Endowed Chair in Dementia Research and inaugural Director of the Clem Jones Centre for Ageing Dementia Research at the Queensland Brain Institute in Brisbane (Australia). Professor Götz studied biochemistry in Switzerland and earned his PhD in immunology with Nobel Laureate Köhler in Germany. After postdoctoral work at UCSF and at Novartis, he became a group leader in Zürich, before moving to the University of Sydney in 2005, and to the University of Queensland (Queensland Brain Institute) in 2012. His laboratory focuses on gaining a mechanistic understanding of Alzheimer's disease, exploring anti-tau antibodies, and developing therapeutic ultrasound into a treatment strategy for Alzheimer's disease. His team has built a clinical trial-ready investigational device that is currently being used in a safety trial in study participants with Alzheimer's disease.



Kaye Hewson

Director Australian Teletrial Program, Office of Research and Innovation Precision Medicine and Research

Kaye is a registered nurse who has been fortunate in shifting her career to policy and program roles with a focus on innovation, change and translation of clinical research both within the Department of Health and in Hospital Health Services. More recently Kaye was tasked in setting up a Genomic Institute in Metro North HHS with a focus on enabling a continuous pipeline of translational clinical research into practice, workforce development. And industry partnerships., research and education. Kaye has worked nationally leading the *Health Policy and Advisory Committee for new Technology (HealthPACT)* program, and as the Queensland representative for the Nationally Funded Centre program advocating for and evaluating specialist services across Australia.



Kaye is passionate about improving patient outcomes and their lived experience when accessing health care and now offering new and innovative pathways of care within the Australian Teletrial Program

Associate Professor Roger M Clarnette, MB BS PhD FRACP

Geriatrician in the Department of Community and Geriatric Medicine, Fremantle Hospital and Health Service, WA.

Other appointments:

- Medical Director, Australian Alzheimer's Research Foundation.
- Clinical Associate Professor, Medical School, University of Western Australia.
- Senior Sessional Member, State Administrative Tribunal, WA.
- Deputy Head of Department, Geriatric Medicine, Fiona Stanley Fremantle Hospitals Group, Western Australia.



Ms Roseanne Hogarth

Clinical Nurse Consultant and the Research Coordinator of the Curran Aging Research Unit at Hornsby Ku-ring-gai Hospital, NSW.

Other appointments:

- Roseanne Hogarth is a Clinical Nurse Consultant and the Research Coordinator of the Curran Aging Research Unit at Hornsby Ku-ring-gai Hospital; she has held this position since 2000. Roseanne is co-author of the medical text Physical Comorbidities of Dementia and the Consumer Edition she holds a Masters in Health Informatics; her special interests are consumer education on dementia prevention, management and cognitive research.



Dr Lars Nelleman

Senior Medical Director, Singapore joined Cerecin Pty Ltd in 2019.

- In this role, Dr. Nelleman provides medical and scientific management of clinical trials and clinical research programs.
- Prior to joining Cerecin, Dr. Nelleman worked with Lundbeck as vice president and regional medical director, Asia Pacific for 15 years, based in Singapore. In that role, he initiated, executed, and oversaw numerous clinical trials in the region. All Lundbeck clinical trials were within the disease areas of neurology and psychiatry.
- Dr. Nelleman started his career in clinical research as active investigator during his residency five (5) years at various Copenhagen City University hospitals. Hereafter he joined the pharmaceutical industry, initially Novo Nordisk and later Lundbeck



Dr. Nelleman has a degree in Medicine from Copenhagen University 1

Dr Steven Gourlay

Chief Executive Officer – Actinogen

Dr Gourlay joined Actinogen in December 2020 as consultant CMO and appointed as CEO and Managing Director in March 2021. He has more than 30 years' experience in the development of novel therapeutics and significant drug regulatory experience. Formerly the founding Chief Medical Officer at US-based Principia Biopharma Inc., Dr Gourlay was responsible for the supervision of multiple pre-clinical, first-in-human, Phase 2 and 3 clinical trial programs for four small molecules in orphan immunological diseases, multiple sclerosis and cancer. The data generated by these trials, and Dr Gourlay's roadshow presentations, supported a successful NASDAQ IPO of Principia Biopharma Inc. in 2018.



Prior to Principia Biopharma, Dr Gourlay was a Partner at GBS Venture Partners, where he was instrumental in the development and exit of multiple clinical stage therapeutic companies. He has held positions of increasing responsibility at Genentech, Inc. in the areas of pharmacoepidemiology and early clinical development.

Dr Gourlay holds a Bachelor of Medicine, Bachelor of Surgery (MB,BS) from the University of Melbourne, a PhD in Medicine from Monash University, an MBA from Macquarie University and is a fellow of the Royal Australian College of Physicians (FRACP). He is also a specialist physician in general internal medicine.

Dr CJ Barnum

Head of Neuroscience INmune BIO

As the Head of Neuroscience at INmune Bio, Dr. CJ Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academia and industry, including Emory University, FPRT Bio., SonosBio, and most recently Takeda Pharmaceuticals. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Dr. Barnum has been working with XPro1595 for more than a decade, first at Emory University with Dr. Malú Tansey and subsequently as a consultant for FPRT Bio., Inc. and INmune Bio, before joining INmune Bio full time in 2018. Dr. Barnum's research has been supported by NIH, The Michael J Fox Foundation, and the Alzheimer's Association. He received his PhD in Neuroscience from Binghamton University

